Evidence mapPaperPMID 34804155Full record

ArticleGastroenterology research and practice2021

An Experimental Study: Benefits of Digoxin on Hepatotoxicity Induced by Methotrexate Treatment.

Banu Taskin, Mümin Alper Erdoğan, Gürkan Yiğittürk, Sibel Alper, Oytun Erbaş

Open access · goldAbstract read
In one paragraph

Article in Gastroenterology research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Banu TaskinDepartment of Dermatology, Koc University Hospital, Istanbul, Turkey.ORCID https://orcid.org/0000-0002-9651-9258
Mümin Alper ErdoğanDepartment of Physiology, Faculty of Medicine, Izmir Katip Celebi University, Izmir, Turkey.ORCID https://orcid.org/0000-0003-0048-444X
Gürkan YiğittürkDepartment of Histology and Embryology, Faculty of Medicine, Mugla University, Muğla, Turkey.ORCID https://orcid.org/0000-0002-5315-253X
Sibel AlperDepartment of Dermatology, Faculty of Medicine, Koc University, Istanbul, Turkey.ORCID https://orcid.org/0000-0001-9086-2250
Oytun ErbaşDepartment of Physiology, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey.ORCID https://orcid.org/0000-0001-5427-8428
Koç University · TRIstanbul Bilim University · TRIzmir Kâtip Çelebi University · TRMuğla University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of the study is to examine the possible therapeutic effects of a known cardiac glycoside, digoxin, on a rat model of MTX-induced hepatotoxicity.

methodsThe study was conducted on twenty-four male rats. While eighteen rats received a single dose of 20 mg/kg MTX to obtain an injured liver model, six rats constituted the control group. Also, the eighteen liver toxicity model created rats were equally divided into two groups, one of which received digoxin 0.1 mg/kg/day digoxin (Group 1) and the other group (Group 2) was given saline (% 0.9NaCl) with a dose of 1 ml/kg/day for ten days. Following the trial, the rats were sacrificed to harvest blood and liver tissue samples to determine blood and tissue MDA, serum ALT, plasma TNF-

resultsMTX's structural and functional hepatotoxicity was observable and evidenced by relatively worse histopathological scores and increased biochemical marker levels. Digoxin treatment significantly reduced the liver enzyme ALT, plasma TNF-

conclusionWe suggest that digoxin has an anti-inflammatory and antihepatotoxic effect on the MTX-induced liver injury model.

Identifiers

PMID34804155
PMCPMC8598353
OpenAlexW3211740346

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.